Compliance & Validation — Documented
GxP validated, 21 CFR Part 11, HIPAA, SOC 2 Type II, ISO 27001
Saama Technologies
AI clinical analytics platform accelerating drug development through smarter data analysis.
Saama's Life Science Analytics Cloud leverages AI to transform clinical trial operations, medical monitoring, safety surveillance, and regulatory intelligence. Their platform helps pharma and biotech companies reduce study timelines, improve data quality, and make faster, more confident decisions throughout development.
- Headquarters
- Campbell, United States
- Founded
- 1997
- Compliance
- GxP, 21 CFR Part 11, HIPAA, SOC 2 Type II, ISO 27001
- Deployment options
- cloud, private-cloud
- Website
- https://www.saama.com
- https://www.linkedin.com/company/saama-technologies
Categories
AI Use Cases
- Case Processing Automation
- Clinical Data Management
- Signal Detection & Aggregate Reporting
Vendor Scorecard
100% — Complete coverage. Coverage score — how completely Atlas documents Saama Technologies across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Deployment & Hosting — Documented
cloud, private cloud
Pricing Transparency — Documented
Enterprise license / per study
Implementation & Onboarding — Documented
3–6 months
Organization & Role Fit — Documented
Mid-Size Biotech, Large Pharma, Top 20 Pharma, CRO / CDMO, Clinical Operations, Data Management, Pharmacovigilance
Solution Scope — Documented
Adverse Event Detection, Clinical Data Management, Natural Language Processing
Company Viability — Documented
Series D, $62.0M raised, 450+ employees, Founded 1997
Always ask the vendor
Not captured in Atlas data — confirm directly. Excluded from the score above.
Data Rights & IP
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Model Credibility & Explainability
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?
Evidence & Outcomes
Pfizer expanded collaboration following accelerated COVID-19 vaccine data review
Saama's AI-driven clinical analytics supported Pfizer's review of clinical trial data during its COVID-19 vaccine program; the companies subsequently expanded their relationship across Pfizer's broader R&D data operations.
press release (Saama (Business Wire)) · 2024-02-12 — Partner: Pfizer
Questions to Ask This Vendor
- How does the AI signal detection integrate with our existing safety database?
- What CDISC standards does the platform natively support?
- Can the NLP models be retrained on our internal nomenclature?